The General Hospital Corporation

Irene Scarfo

Marcela V Maus

Mark Cobbold

Described herein are methods for producing and utilizing an alternative signal 1 domain to construct an optimally signaling CAR. Alternative signal 1 domains of the present technology are based on alternatives to CD3&#x3b6;, including mutated ITAMs from CD3&#x3b6; (which contains 3 IT AM motifs), truncations of CD3&#x3b6;, and alternative splice variants known as CD3s, CD3 theta, and artificial constructs engineered to express fusions between CD3s or CD30 and CD3&#x3b6;. CAR polypeptides comprising alternative signal 1 domains are utilized to engineer CAR T cells. Further, this technology related to methods of treating cancer by administering to a subject in need thereof CAR T cells comprising alternative signal 1 domains.

Chimeric antigen receptors based on alternative signal 1 domains

Described herein are chimeric antigen receptors (CARs) targeting CD37, as well as related molecules and methods.

Growing community of inventors

Cambridge, MA, United States of America

Irene Scarfo